Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 241500
Corporate User License Price USD 10500
Corporate User License Price INR 724500
Site License Price USD 7000
Site License Price INR 483000
Request a Quote

Report Title

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Pipeline Review, H2 2017

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Pipeline Review, H2 2017


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Pipeline Review, H2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Pipeline Review, H2 2017



Executive Summary

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Pipeline Review, H2 2017

Summary

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity.

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 24 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 1, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Melanoma, Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Lung Cancer, Mantle Cell Lymphoma, Neurodegenerative Diseases, Neurology, Non-Hodgkin Lymphoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sickle Cell Disease, Solid Tumor, Thalassemia, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Asthma, Becker Muscular Dystrophy, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), CNS Lymphoma, Cognitive Disorders, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Gallbladder Cancer, Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, T-Cell Leukemia and Thyroid Cancer.

The latest report Histone Deacetylase 2-Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)

The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Overview 8

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 16

Products under Development by Universities/Institutes 23

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Therapeutics Assessment 25

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Companies Involved in Therapeutics Development 31

4SC AG 31

Celgene Corp 31

Chipscreen Biosciences Ltd 32

Curis Inc 33

HitGen LTD 34

Italfarmaco SpA 34

Medivir AB 35

MEI Pharma Inc 35

Merck & Co Inc 36

Sigma-Tau SpA 37

Yungjin Pharm Co Ltd 37

Zhejiang Hisun Pharmaceutical Co Ltd 38

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Drug Profiles 39

4SC-202-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ACY-1035-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ACY-1071-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ACY-738-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ACY-957-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

CS-3158-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CUDC-907-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

givinostat-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

HG-3001-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

largazole-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

pracinostat-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

RCY-1305-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

RCY-1497-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

RCY-1992-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

remetinostat-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

resminostat-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecule to Inhibit HDAC2 for Oncology-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Small Molecules to Inhibit HDAC2 for Neurological Disorders-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

ST-3595-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Synthetic Peptide to Inhibit HDAC for Prostate Cancer-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

tucidinostat-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

vorinostat-Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

YPL-001-Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Dormant Products 99

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Discontinued Products 102

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Product Development Milestones 103

Featured News & Press Releases 103

Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 103

Jul 19, 2017: Regenacy Pharmaceuticals Presents Data Demonstrating that HDAC1,2 Inhibition Improved Cognitive Function in Mouse Models of Alzheimer's Disease at the Alzheimer's Association International Conference 104

Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome 104

Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 105

May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 106

May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 107

Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 107

Apr 11, 2017: New mechanistic insights into 4SC-202's epigenetic mode of action 108

Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 109

Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup 110

Jan 11, 2017: Regenacy Pharma's HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities 110

Jan 11, 2017: Regenacy Pharma's HDAC2 Inhibitor ACY-1035 Demonstrates Potent Anti-Leukemic Activities 111

Dec 16, 2016: First patient enrolled in pivotal RESMAIN study of resminostat in CTCL 112

Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 112

Dec 04, 2016: Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HBG) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia 113

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 25

Number of Products by Stage and Mechanism of Actions, H2 2017 25

Number of Products by Routes of Administration, H2 2017 27

Number of Products by Stage and Routes of Administration, H2 2017 27

Number of Products by Molecule Types, H2 2017 29

Number of Products by Stage and Molecule Types, H2 2017 29

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 15

Number of Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 21

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 22

Number of Products under Investigation by Universities/Institutes, H2 2017 23

Products under Investigation by Universities/Institutes, H2 2017 24

Number of Products by Stage and Mechanism of Actions, H2 2017 26

Number of Products by Stage and Route of Administration, H2 2017 28

Number of Products by Stage and Molecule Type, H2 2017 30

Pipeline by 4SC AG, H2 2017 31

Pipeline by Celgene Corp, H2 2017 32

Pipeline by Chipscreen Biosciences Ltd, H2 2017 33

Pipeline by Curis Inc, H2 2017 34

Pipeline by HitGen LTD, H2 2017 34

Pipeline by Italfarmaco SpA, H2 2017 35

Pipeline by Medivir AB, H2 2017 35

Pipeline by MEI Pharma Inc, H2 2017 36

Pipeline by Merck & Co Inc, H2 2017 37

Pipeline by Sigma-Tau SpA, H2 2017 37

Pipeline by Yungjin Pharm Co Ltd, H2 2017 38

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 38

Dormant Products, H2 2017 99

Dormant Products, H2 2017 (Contd..1), H2 2017 100

Dormant Products, H2 2017 (Contd..2), H2 2017 101

Discontinued Products, H2 2017 102

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

4SC AG

Celgene Corp

Chipscreen Biosciences Ltd

Curis Inc

HitGen LTD

Italfarmaco SpA

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Sigma-Tau SpA

Yungjin Pharm Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Therapeutic Products under Development, Key Players in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Therapeutics, Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Pipeline Overview, Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Pipeline, Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person